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Mitra Clip: Looking at its chance in developing 
country
Yoga Yuniadi
Looking at developed countries data on valvular heart diseases, mitral regurgitationis one of the most commonly encountered valvular lesions. Moderate to severe regurgitation 
present in up to 30% of patients with various clinical 
subsets. Mitral regurgitation severity has been positively 
correlated with the subsequent development of heart 
failure and death.1-4
The 2008 ACC/AHA guidelines describe three 
types of MV operations: (i) MV repair; (ii) MV 
replacement with chor
dal preservation; and (iii) MV replacement with 
removal of the mitral apparatus. The ACC/AHA 
guidelines support MV surgery for patients with severe 
(3– 4+) MR who are symptomatic with preserved LV 
size and function, asymptomatic with LV dysfunction 
or increased LV size, who have recent onset atrial 
fibrillation or evidence of pulmonary hypertension, or 
in symptomatic patients with severe LV dysfunction 
(LVEF ≤30%) despite optimal medical therapy.
Currently, a new percutaneous approach for 
treating mitral regurgitation (so called MitraClip) 
which involves mechanical edge-to-edge coaptation 
of the mitral leaflets has been developed. The device 
mechanism is analogous to the surgical Alfieri 
technique.MitraClip (Abbott Vascular, Abbott Park, 
Illinois, USA; formerly manufactured by EvalveInc, 
Menlo Park, California, USA) has been approved by 
FDA last year.5Since 2008 almost 4000MitraClip have 
been implanted all over the world (Figure 1).6Overall, 
the procedure has proven to be safe with exceedingly 
low rates of fatal or life-threatening complications. 
Additionally, significant improvements in functional 
capacity and quality of life have been reported 
following MitraClip implantation. However, apart 
from these encouraging results, open questions remain 
to be addressed, particularly about long term durability 
and clinical efficacy, and the selection of the most 
appropriate candidates for MitraClip implantation. 
As the experience with this procedure continues to 
expand, larger studies are expected that will help to 
further define the role of the MitraClip procedure 
among established therapies.6
Patient selection is utmost important to gain 
procedural success. Two main criteria of Endovascular 
Valve Edge-to-Edge Repair Study (EVEREST) for 
patient selection are clinical and anatomical criteria. 
Clinical criteria comprise of moderate-to-severe (3+) 
and severe (4+) mitral regurgitation, meeting class I 
indications for intervention (MVR or mitral valve 
replacement) by the ACC/AHA or ESC guidelines, 
mitral reguritationaetiology limited to degenerative 
or functional, non-rheumatic or -endocarditic origin, 
andhigh surgical risk by EuroSCORE or STS scores. 
Anatomical criteria comprise of mitral regurgitation 
originating from the central 2⁄3 of the valve, mitral 
orifice area ≥4 cm2, meeting criteria for degenerative 
mitral regurgitation (i.e. flail gap <10 mm, flail 
width <15 mm), meeting criteria for functional 
mitral regurgitation (i.e. coaptation depth ≤ 11 mm, 
coaptation length ≥ 2 mm).7, 8
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Recently published paper of a 4-year follow-up 
shows no differences in the primary end point between 
the MitraClip procedure and surgery.  The clip group 
had significantly more follow-up surgeries for residual 
mitral regurgitation.9The study shows the comparison 
of the procedures in a surgical population favors 
surgery as compare to clip, however it provides useful 
information about the long-term durability of the 
device. Treatment with the MitraClip was associated 
with mortality rates similar to surgery at one year, but 
the degree of MR reduction was less with percutaneous 
repair. At one year, approximately 20% of MitraClip 
patients required mitral-valve surgery to treat moderate 
or severe MR compared with only 2.2% of patients 
treated with surgery.
Reynolds et al.10 analyze 12-month data cost-
effectiveness on the MitraClip from EVEREST II and 
estimated indexed admission costs, costs for follow-up 
hospitalizations, and resource-based costs including 
rehabilitative and long-term care services. These were 
compared with expenses associated with conventional 
mitral valve surgery.Researchers used the assumed price 
of the MitraClip (18,000 USD) in the United States, 
where the system is still not commercially available, 
and the European sales price of about 26,200 USD. At 
the U.S. price, use of the system reduced overall costs 
by 2,200 USD per patient, indicating that this method 
is economically dominant. However, at the European 
price, overall costs were6,192 USD higher than 
conventional surgery with a cost >400,000 USD per 
quality-adjusted life year (QALY) gained.In Indonesia, 
MitraClip price is even higher (up to 33,000 USD)
while the surgical cost is lower compare to Europe.This 
situations make clip procedure far more costly.  
In some developing countries, such as Indonesia, 
where universal coverage of health insurance conducted 
and manage by government only best proven and 
affordable medical technologies will allowed to be 
implemented. In other hand surgical valves procedure 
considered to be at its lowest cost making clip only 
cost-effective when surgical repair is contraindicated. 
Furthermore, in developing countries significant 
number of mitral regurgitation is related to rheumatic 
heart disease. Unfortunately, currently MitraClip is 
contraindicated for use in Rheumatic mitral disease.5
As a conclusion we can cite the EVEREST II 
author Dr. Mauri’s saying9: “In a patient where 
surgical risk is very high, it may make sense to avoid 
the up-front risk if a good result can be achieved with 
a less invasive procedure. In good surgical candidates, 
where more complete treatment can be achieved with 
surgery with minimal risk, up-front surgery makes 
more sense.” In our setting at developing country 
concerning of all mentioned studies results, MitraClip 
should be limited for whom surgery is not desired due 
to its very high risk. Nowadays, surgical repair must 
still be the procedure of choice for mitral regurgitation 
treatment.
Figure 1. Number of MitraClip procedures in Europe after CE mark approval 2008. Note 
that between April and September 2011, MitraClip implantations were interrupted as a result 
of a technical defect in the delivery system.6
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